Solvay’s Pulzium Data Does Not Cross The Atlantic: FDA Panel Unanimously Opposes Approval

Cardio-Renal committee advises Solvay to develop data with greater diversity of patients by location and medical history to improve chances for approval of the atrial fibrillation drug.